BOSE P ET AL: "Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)", LEUKEMIA RESEARCH REPORTS 2013 ELSEVIER LTD GBR, vol. 2, no. 1, 22 January 2013 (2013-01-22), pages 12-14, XP002740451, ISSN: 2213-0489 (B1)

ZHANG W ET AL: "Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim", CANCER RESEARCH, vol. 70, no. 6, 15 March 2010 (2010-03-15) , pages 2424-2434, XP002740443, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-09-0878 (B1)

FALCHOOK G S ET AL: "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 13, no. 8, 1 August 2012 (2012-08-01) , pages 782-789, XP002727794, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(12)70269-3 [retrieved on 2012-07-16] (B1)

FENG JIANHUA ET AL: "Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation", THE JOURNAL OF BIOLOGICAL CHEMISTRY 20 AUG 2004, vol. 279, no. 34, 20 August 2004 (2004-08-20), pages 35510-35517, XP002740653, ISSN: 0021-9258 (B1)

FLAHERTY KEITH T ET AL: "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US , vol. 367, no. 18 1 November 2012 (2012-11-01), pages 1694-1703, XP002725869, ISSN: 0028-4793, DOI: 10.1056/NEJMOA1210093 Retrieved from the Internet: URL:http://www.nejm.org/doi/pdf/10.1056/NE JMoa1210093 [retrieved on 2012-09-29] (B1)

GILES FRANCIS ET AL: "MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant chronic myelogenous leukemia (CML)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), page 52a, XP009124755, ISSN: 0006-4971 (B1)

J. G. GREGER ET AL: "Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations", MOLECULAR CANCER THERAPEUTICS, vol. 11, no. 4, 1 April 2012 (2012-04-01), pages 909-920, XP055057160, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-11-0989 (B1)

J. M. GOZGIT ET AL: "Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies", MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 6, 11 April 2011 (2011-04-11) , pages 1028-1035, XP055056925, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-10-1044 (B1)

JI Z ET AL: "p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, US, vol. 132, no. 2, 1 February 2012 (2012-02-01), pages 356-364, XP002694638, ISSN: 1523-1747, DOI: 10.1038/JID.2011.313 [retrieved on 2011-10-13] (B1)

JI ZHENYU ET AL: "Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 AUG 2013, vol. 19, no. 16, 27 June 2013 (2013-06-27) , pages 4383-4391, XP002734225, ISSN: 1078-0432 (B1)

KAO CHIA-LI ET AL: "Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells", CANCER LETTERS 28 DEC 2009, vol. 286, no. 2, 28 December 2009 (2009-12-28), pages 250-259, XP002740446, ISSN: 1872-7980 (B1)

KHOURY H JEAN ET AL: "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure", BLOOD 12 APR 2012, vol. 119, no. 15, 12 April 2012 (2012-04-12), pages 3403-3412, XP002740449, ISSN: 1528-0020 (B1)

KOJIMA KENSUKE ET AL: "Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML", CELL CYCLE (GEORGETOWN, TEX.) DEC 2006, vol. 5, no. 23, December 2006 (2006-12), pages 2778-2786, XP002740450, ISSN: 1551-4005 (B1)

KOJIMA KENSUKE ET AL: "Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia", BLOOD 1 AUG 2006, vol. 108, no. 3, 1 August 2006 (2006-08-01), pages 993-1000, XP055140017, ISSN: 0006-4971 (B1)

KOJIMA KENSUKE ET AL: "Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells", CANCER RESEARCH 1 APR 2007, vol. 67, no. 7, 1 April 2007 (2007-04-01), pages 3210-3219, XP002740444, ISSN: 0008-5472 (B1)

LIU DINGXIE ET AL: "Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways", THYROID : OFFICIAL JOURNAL OF THE AMERICAN THYROID ASSOCIATION AUG 2008, vol. 18, no. 8, August 2008 (2008-08), pages 853-864, XP002740459, ISSN: 1050-7256 (B1)

LONG JIANTING ET AL: "Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia", BLOOD 8 JUL 2010, vol. 116, no. 1, 8 July 2010 (2010-07-08), pages 71-80, XP002740447, ISSN: 1528-0020 (B1)

LU WENGE ET AL: "Activation of p53 by roscovitine-mediated suppression of MDM2 expression", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 20, no. 25, 31 May 2001 (2001-05-31), pages 3206-3216, XP002292792, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1204412 (B1)

MARTINELLI E ET AL: "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER NOV 2013, vol. 133, no. 9, 30 April 2013 (2013-04-30), pages 2089-2101, XP002740445, ISSN: 1097-0215 (B1)

NAGMA KHAN ET AL: "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors", BIOCHEMICAL JOURNAL, vol. 409, no. 2, 15 January 2008 (2008-01-15), page 581, XP055074060, ISSN: 0264-6021, DOI: 10.1042/BJ20070779 (B1)

TIANJUN ZHOU ET AL: "Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 77, no. 1, 30 November 2010 (2010-11-30), pages 1-11, XP055065379, ISSN: 1747-0277, DOI: 10.1111/j.1747-0285.2010.01054.x (B1)

US-A1- 2011 319 378 (B1)

US-A1- 2012 077 683 (B1)

US-A1- 2012 196 823 (B1)

US-A1- 2013 245 039 (B1)

WANG ET AL: "Clinical experience of MEK inhibitors in cancer therapy", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1773, no. 8, 1 August 2007 (2007-08-01), pages 1248-1255, XP022181677, ISSN: 0167-4889, DOI: 10.1016/J.BBAMCR.2006.11.009 (B1)

ZAULI GIORGIO ET AL: "Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 FEB 2011, vol. 17, no. 4, 15 February 2011 (2011-02-15), pages 762-770, XP002740448, ISSN: 1078-0432 (B1)

CHITHRA D PALANI ET AL: "Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 1, 3 August 2010 (2010-08-03) , pages 25-36, XP035000732, ISSN: 1573-0646, DOI: 10.1007/S10637-010-9510-7 (B1)